Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia
- 1 June 2002
- journal article
- case report
- Published by Springer Nature in Leukemia
- Vol. 16 (6), 1028-1034
- https://doi.org/10.1038/sj.leu.2402529
Abstract
To investigate the role of the cell cycle regulators p21Waf1, p27Kip1, retinoblastoma (Rb), and cyclin D1 in Richter's transformation of chronic lymphocytic leukemia (CLL), we analyzed 19 CLL and eight Richter's syndrome (RS) tumors, previously characterized for p53 and ARF/INK4a abnormalities. p21Waf1immunohistochemical expression was negative in 12 of 15 CLL (80%), whereas it was moderate or strong in three of seven RS (43%). p21Waf1 gene was in germline configuration in all the tumors analyzed. Four immunohistochemical patterns of p53 and p21Waf1 expression were observed: (1) p53−/p21− in 10 of 15 CLL (67%), but only in two of six RS (33%); (2) p53+/p21+ in three CLL (20%) and two RS (33%); (3) p53−/p21+ in one RS; and (4) p53++/p21− in two CLL and one RS. Two p53+/p21+ CLL evolved into RS. p53 mutations clustered around the p53++/p21− (two CLL and one RS) and p53−/p21− (one CLL and one RS) tumors. While the majority of CLL displayed strong p27 immunoreactivity, RS tumors were constantly p27-negative. p27Kip1 gene was in germline configuration in all the tumors analyzed. Most CLL cases were negative for Rb expression. In contrast, all RS exhibited strong Rb expression. Cyclin D1 overexpression was only detected in one CLL evolving into RS and one RS. In conclusion, a p53+/p21− immunohistochemical pattern is shown exclusively by p53-mutated CLL/RS. Additionally, our results suggest a possible implication of moderate/strong p21Waf1 expression, loss of p27 expression, and cyclin D1 overexpression in the Richter's transformation of CLL.Keywords
This publication has 40 references indexed in Scilit:
- Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphomaLeukemia, 2000
- INK4a/ARFLocus Alterations in Human Non-Hodgkin's Lymphomas Mainly Occur in Tumors with Wild-Type p53 GeneThe American Journal of Pathology, 2000
- Loss of p16/INK4A Protein Expression in Non-Hodgkin's Lymphomas Is a Frequent Finding Associated with Tumor ProgressionThe American Journal of Pathology, 1998
- Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomasNature Medicine, 1997
- Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signalsCell, 1994
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993
- Richter's syndrome: a report on 39 patients.Journal of Clinical Oncology, 1993
- The retinoblastoma gene product regulates progression through the G1 phase of the cell cycleCell, 1991
- p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.Proceedings of the National Academy of Sciences, 1991
- The E2F transcription factor is a cellular target for the RB proteinCell, 1991